Long-Term Safety from the Raltegravir Clinical Development Program by Teppler, Hedy et al.
40  Current HIV Research, 2011, 9, 40-53   
 
  1570-162X/11 $58.00+.00  © 2011 Bentham Science Publishers Ltd. 
Long-Term Safety from the Raltegravir Clinical Development Program 
Hedy Teppler
*, Deborah D. Brown, Randi Y. Leavitt, Peter Sklar, Hong Wan, Xia Xu,  
Fabio Lievano, Heidi P. Lehman, T. Christopher Mast and Bach-Yen T. Nguyen 
Merck Research Laboratories, North Wales, PA, USA 
Abstract: Background: Raltegravir has demonstrated potent and durable efficacy and a favorable safety profile in 3 phase 
III studies in treatment-naïve and treatment-experienced patients with HIV-1 infection. This manuscript provides a review 
of the raltegravir safety profile using data from these and other studies in the clinical development program. 
Methods: Comprehensive 96-week safety data from STARTMRK (raltegravir versus efavirenz, each with 
tenofovir/emtricitabine) and BENCHMRK (raltegravir versus placebo, each with optimized background therapy) are 
summarized. A cumulative meta-analysis of raltegravir 400 mg bid was conducted across the entire development program. 
Results: In STARTMRK, drug-related adverse events (AEs) occurred less frequently with raltegravir than efavirenz. In 
BENCHMRK, the most common drug-related AEs occurred at generally similar frequencies in both groups. Drug-related 
serious AEs were uncommon. Rash was observed in raltegravir-treated patients at a higher frequency than placebo but a 
lower frequency than efavirenz. Depression and immune reconstitution inflammatory syndrome occurred at similar rates 
for raltegravir and comparators. Isolated elevations of creatine kinase were more common with raltegravir than placebo 
but occurred without clinical manifestations. The frequency of aminotransferase elevations was greater in patients with 
viral hepatitis co-infection, but similar in the raltegravir and comparator groups. The relative risk (95% CI) of cancer was 
0.75 (0.30, 1.91) indicating no difference between raltegravir and comparator. Overall trends in the cumulative meta-
analysis were similar to those observed in the phase III studies. 
Conclusions: Long-term data from the phase III clinical trials demonstrate that raltegravir was generally well-tolerated in 
both treatment-naïve and treatment-experienced patients with HIV infection. 
Keywords: Raltegravir, integrase inhibitor, long-term safety, BENCHMRK, STARTMRK. 
INTRODUCTION 
  Treatment with a combination of highly active 
antiretroviral agents (HAART) is the standard of care for 
patients with human immunodeficiency virus (HIV) 
infection, yet is often complicated by the development of 
antiretroviral resistance, toxicity and adverse experiences 
(AEs) associated with one or more agents, underlying 
medical conditions, drug interactions, and personal 
preference of patients and care-providers. New therapies are 
needed. 
  Raltegravir is an HIV integrase inhibitor that blocks HIV 
replication by specific inhibition of proviral DNA-strand 
transfer, a mechanism of action distinct from that of other 
approved classes of antiretroviral drugs [1]. Raltegravir has 
potent in vitro activity against HIV-1 strains susceptible or 
resistant to other antiretroviral drug classes 
1. Initially 
approved in the United States and other countries in 2007 to 
be used in combination therapy for the treatment of HIV 
infection in patients failing previous HAART, raltegravir is 
now approved for use in both treatment-naïve and treatment- 
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experienced patients, based on the demonstration of potent 
and durable efficacy, good tolerability and a favorable safety 
profile in 3 phase III studies: Protocol 021 (known as 
STARTMRK) in treatment-naïve patients [2,3], and 
Protocols 018 and 019 (known as BENCHMRK-1 and 
BENCHMRK-2, respectively) in treatment-experienced 
patients [4-6]. 
  This manuscript provides a review of the safety profile of 
raltegravir, summarizing the comprehensive 96 week safety 
data from these phase III trials. A number of conditions of 
interest were identified for specific review either based on 
data from the raltegravir clinical trials, or because they have 
been reported as post-marketing AEs for raltegravir or were 
associated with other antiretroviral agents. These events 
include serious rash/Stevens Johnson syndrome (SJS), 
lipodystrophy, immune reconstitution inflammatory 
syndrome (IRIS), increase in liver enzymes and related 
clinical hepatic events, elevations of creatine phosphokinase 
(CK) with clinical manifestations including rhabdomyolysis 
and myopathy, and depression including suicidal ideation 
and behaviors. Malignancies are also specifically examined 
because the initial analysis of the BENCHMRK data 
suggested an imbalance in the occurrence of cancers; 
however, review of subsequent data does not suggest an 
increased risk of malignancy with raltegravir treatment. A 
cumulative meta-analysis across the entire development 
program was also conducted to examine the comprehensive 
safety of the 400 mg bid raltegravir dose. In aggregate, the 
long-term data from the phase III clinical trials demonstrates 
that raltegravir was generally well-tolerated in both Long-Term Safety of Raltegravir  Current HIV Research, 2011, Vol. 9, No. 1    41 
treatment-naïve and treatment-experienced HIV-infected 
patients. 
MATERIAL AND METHODS 
  STARTMRK is a multicenter, double-blind (DB), 
randomized, active-controlled study to evaluate the safety 
and antiretroviral activity of raltegravir versus efavirenz, 
each in combination with tenofovir/emtricitabine, in 
treatment-naïve HIV-infected patients [2,3]. BENCHMRK-1 
and -2 are identical multicenter, double-blind, randomized, 
placebo-controlled studies to evaluate the safety and 
antiretroviral activity of raltegravir in combination with an 
optimized background therapy (OBT), versus optimized 
background therapy alone, in HIV-infected patients with 
documented 3-class resistance; both studies included an 
open-label treatment option for patients with virologic 
failure [4-6]. BENCHMRK data presented here focus on the 
DB treatment phase and are shown for the 2 studies 
combined. An independent data and safety monitoring board 
periodically monitored the blinded safety and efficacy results 
of all 3 trials. Because of the difference in baseline 
characteristics, especially HIV disease stage, concurrent 
conditions and medications in the two populations studied, 
the safety data are presented separately for treatment-naïve 
and treatment-experienced populations except for the 
malignancy analysis. 
  AE terms were coded using the Medical Dictionary for 
Drug Regulatory Affairs (MedDRA, Version 12.0). 
Investigators were required to assess each AE for both 
intensity and causal relationship to study regimen. Intensity 
was assessed as mild, moderate, or severe based upon degree 
of interference with routine activities. Causality was assessed 
based on overall investigator judgment as definitely, 
probably, possibly, probably not, or definitely not related to 
raltegravir or comparator (efavirenz or placebo) either alone 
or in combination with other background therapy 
(tenofovir/emtricitabine or OBT). AEs with causality 
assessment of possible, probable, or definite were considered 
"drug-related." Serious AEs (SAEs) were those which met 
any of the following criteria: resulted in death, led to or 
prolonged hospitalization, was a persistent or significant 
disability, was considered life threatening, a congenital 
anomaly (in the offspring of patient following prenatal 
exposure to raltegravir), a cancer, an overdose, or an "other 
important medical event" in the judgment of the investigator. 
  The following safety issues were identified from clinical 
trials, post-licensure reports, or as general concerns for 
antiretroviral agents: rash, SJS, depression including suicidal 
ideation and behaviors, IRIS, lipodystrophy, elevations of 
CK with clinical manifestations including rhabdomyolysis 
and myopathy, and increase in liver enzymes and related 
clinical hepatic events. For the assessment of these selected 
safety issues, all related specific MedDRA terms present in 
the database were included; the list of specific terms is 
provided in the respective sections. Frequencies of AEs 
(both all causality and drug related) are provided for all 
populations. Exposure-adjusted rates are provided for the 
BENCHMRK studies only. 
  Laboratory abnormalities were graded using Division of 
AIDS (DAIDS) toxicity criteria for the laboratory test of 
interest, identifying changes that represented a worsened 
grade from baseline, as patients were permitted to enroll with 
substantial baseline laboratory abnormalities. Baseline 
values were those obtained at the baseline study visit before 
initiation of study therapy. In the BENCHMRK studies, all 
clinical AIDS defining conditions (ADC) were reported as 
submitted by investigators for safety analysis; these events 
were submitted for blinded adjudication for separate 
consideration of confirmed ADCs as an efficacy parameter 
[4-6]. 
 Exposure-adjusted rates are provided for the 
BENCHMRK clinical AEs and laboratory data because of 
unbalanced attrition resulting from higher rates of virologic 
failure in the placebo group; exposure was 708 person-years 
(PYR) for raltegravir and 244 PYR for placebo at the 96 
week analysis. Exposure-adjusted rates provide the number 
of events (clinical AEs or laboratory abnormalities) per 100 
PYR of exposure, using a crude population-based exposure 
adjustment with fixed exposure time; STARTMRK data 
were not exposure-adjusted since the study periods were 
balanced between the 2 treatment groups. 
  Since patients with active hepatitis B or C co-infection 
were permitted to enroll, this review of safety also includes 
specific examination of hepatic safety in co-infected patients. 
  The analysis of malignancy combines data from all 3 
studies and uses all available DB data, including data beyond 
week 96 for some patients. Time-at-risk for patients with 
cancer in the DB phase is from randomization to first cancer 
diagnosis; time at risk for patients without cancer in the DB 
phase is from randomization to data cut-off (if continuing) or 
to 14 days after study discontinuation. Exposure-adjusted 
rate of cancer was the number of patients with cancer per 
100 PYR. Relative risk (RR) and associated exact 95% CI 
were calculated to compare raltegravir with comparator 
during the DB phase. 
  A cumulative meta-analysis was also conducted to 
examine the comprehensive safety of the 400 mg bid 
raltegravir dose across the entire development program. This 
analysis includes all available DB data from Merck studies 
in HIV-infected adults that have been unblinded and 
presented or published: Protocols 004, 005, 032 and 033, in 
addition to 96 week data from the phase III STARTMRK 
and BENCHMRK studies described above. Protocol 004 is a 
dose-ranging phase II study of raltegravir versus efavirenz 
(both with lamivudine and tenofovir) in treatment naïve 
individuals; data up to week 144 are included 
2. Protocol 005 
is a dose-ranging phase II study of raltegravir versus placebo 
(both with OBT) in highly treatment-experienced patients 
[7]; 24-48 weeks of DB data are included. Protocols 032 and 
033 (SWITCHMRK studies) are identical studies of 
raltegravir 400mg bid versus continued lopinavir/ritonavir 
(both with stable background regimens) in patients stably 
suppressed on a lopinavir/ritonavir regimen; DB data 
through week 24 are included [8]. A similar analytical 
approach was used for the cumulative meta-analysis for both 
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AEs and treatment-emergent laboratory abnormalities. The 
focus was combined data from all patients who received 
raltegravir 400mg versus comparator in DB phase. Crude 
exposure adjustment was used to address the different 
durations of therapy in the raltegravir versus comparator 
groups. Details can be found in Supportive/Supplementary 
Material. 
RESULTS 
Phase III Studies 
Demographics 
 Table  1 presents the demographic distribution of the 
treatment groups. The STARTMRK population had a greater 
proportion of non-white race/ethnicity, was younger, and had 
a lower proportion of males than the BENCHMRK 
population. Hepatitis B or C co-infection was present in 
approximately 6% of patients per group in STARTMRK and 
in approximately 16% per group in BENCHMRK. 
Table 1.  Patient Demographics, Phase III Studies  
 
  STARTMRK   BENCHMRK  
 
Raltegravir 
N=281 
Efavirenz 
N=282 
Raltegravir 
N=462 
Placebo 
N=237 
Gender        
Female 19.2%  18.1%  12.3%  11.4% 
Male 80.8%  81.9%  87.7%  88.6% 
Age (Years) 
17 and Under  0.0%  0.0%  0.9%  0.4% 
18 to 64  99.3%  98.6%  97.6%  98.7% 
Over  64  0.7% 1.4% 1.5%  0.8% 
Mean  37.6 36.9 45.7  45.1 
Std.  Dev.  8.97 9.98 8.56  8.12 
Median  37.0 36.0 45.0  45.0 
Range  19 - 67  19 - 71  16 - 74  17 - 70 
Race/Ethnicity 
Asian 12.8%  11.3%  3.5%  2.5% 
Black  11.7% 8.2% 14.1%  11.0% 
Hispanic American  21.4% 23.8% 11.5%  8.0% 
Multi-Racial 12.5%  12.8%  5.6%  5.5% 
Native  American  0.4% 0.4% 0.2%  0.0% 
White 41.3%  43.6%  65.2%  73.0% 
Hepatitis Co-Infection
† 
Hepatitis B or C 
Positive  
6.4% 5.7%  16.7%  15.6% 
 
†Evidence of hepatitis B surface antigen or evidence of HCV RNA by polymerase 
chain reaction (PCR) quantitative test for hepatitic C Virus. In the STARTMRK study 
five patients previously classified as hepatitis B or C positive were subsequently 
identified based on lab tests as being hepatitis B or C negative. In the BENCHMRK -1 
and -2 studies one patient from BENCHMRK-2 was included in the Hepatitis B or C 
positive subgroup due to HCV positive despite a negative HCV antibody as specified 
by the Food and Drug Administration. 
 
Clinical Adverse Experiences 
 Table  2 displays clinical AEs for the STARTMRK and 
BENCHMRK studies, including frequencies of various 
categories of clinical AEs: overall, drug-related, serious, 
serious drug-related, death, discontinuations due to an AE, 
discontinuations due to a drug-related AE, the most frequent 
clinical AEs (reported in at least 10% in any group) 
irrespective of causality, and the most frequent drug-related 
AEs (reported in at least 2% in any group). 
  In STARTMRK, drug-related AEs occurred less 
frequently in the raltegravir group compared to the efavirenz 
group (p-value <0.001). For the various other categories of 
AEs, frequencies were generally similar between the 
raltegravir and efavirenz groups. In BENCHMRK, AEs of 
all categories occurred at similar frequencies between the 
raltegravir and placebo groups; after adjustment for 
exposure, the rates of AEs for raltegravir were in general 
lower than for placebo. 
  In STARTMRK, the most notable difference was for the 
specific AE of dizziness: 8.2% in the raltegravir group 
compared to 36.9% in the efavirenz group; most of these 
reports were considered drug-related: 6.0% vs 34.0%, 
respectively. Otherwise, the most common AEs in both 
treatment groups, irrespective of causality, were diarrhea and 
headache. Diarrhea was reported at a higher frequency in the 
efavirenz group; frequencies of headaches were similar in 
both groups. The most common drug-related AEs of any 
intensity were diarrhea, nausea, fatigue, headache, 
somnolence, abnormal dreams, insomnia, and rash, all of 
which were reported at higher frequencies in the efavirenz 
group than in the raltegravir group. 
  In the BENCHMRK studies, the most common AEs 
irrespective of causality were diarrhea, nausea, upper 
respiratory tract infection, and headache, which occurred at 
similar frequencies in the raltegravir and placebo groups. 
The most common drug-related AEs of any intensity were 
diarrhea, nausea, fatigue, and headache and these occurred at 
generally similar frequencies in both groups. Exposure-
adjusted rates were generally lower for these AEs in the 
raltegravir group compared with the placebo group. 
  In all phase III trials, SAEs considered drug-related 
(possibly, probably or definitely) were uncommon, even in 
treatment-experienced patients with advanced disease. Drug-
related SAEs (number of patients, study day of onset) in the 
raltegravir group in STARTMRK were immune 
reconstitution syndrome (2, d. 7 and d. 29), mental disorder 
(1, d. 76), suicide attempt (1, d. 510), and anemia (1, d. 512). 
Only the SAE of mental disorder led to discontinuation of 
therapy. In the BENCHMRK studies, drug-related SAEs in 
the raltegravir group were genital herpes (1, d. 134), hepatitis 
(1 pt, 2 occurrences, d. 30 and d. 102), gastritis (1 pt, 2 
occurrences, d. 23 and d. 211), renal failure (1, d. 25), and 
accidental overdose (1, d. 233). The case with hepatitis was a 
flare of pre-existing hepatitis B, and the second occurrence 
resulted in discontinuation from study. The case with renal 
failure was considered most likely related to tenofovir in 
OBT (and possibly related to raltegravir) and this patient 
also discontinued from the study. The accidental overdose 
was a dosing error (patient consumed twice the recommen-
ded dose) and was not associated with any clinical AEs. Long-Term Safety of Raltegravir  Current HIV Research, 2011, Vol. 9, No. 1    43 
Table 2.  Summary of Clinical Adverse Experiences, Phase III Studies  
 
STARTMRK BENCHMRK   
Raltegravir 
N=281 
Efavirenz 
N=282 
Raltegravir 
N=462 
PYR=708 
Placebo 
N=237 
PYR=244 
Proportion of Patients 
% %  %  Rate
† % Rate
† 
Clinical Adverse Experience (AE) Summary 
With one or more AEs  94.3  97.2  92.4  60.3  88.6  86.1 
With drug-related
‡ AEs  47.0  78.0  57.8  37.7  58.6  57.0 
With serious AEs  13.2  11.7  23.2  15.1  22.4  21.7 
With serious drug-related
‡ AEs  2.1  1.8  2.8  1.8  3.8  3.7 
Who died  1.1  0.0  2.8  1.8  3.0  2.9 
Discontinued due to AEs  3.6  6.0  3.7  2.4  4.6  4.5 
Discontinued due to drug-related AEs  1.1  4.3  1.5  1.0  1.7  1.6 
Clinical AEs by System Organ Class (Incidence 10%
§) All Causality, All Intensities 
Gastrointestinal Disorders 
Diarrhea 17.1  24.5  22.3  14.5  23.6  23.0 
Nausea 14.2  12.8  13.2  8.6  14.8  14.3 
Vomiting 6.8  8.9  8.0  5.2  10.5  10.2 
General Disorders and Administrative Site Conditions 
Fatigue 6.8  11.7  11.0  7.2  5.5  5.3 
Injection Site Reaction
% NA  NA  10.4  6.8  10.1  9.8 
Pyrexia 11.7  10.3  8.4  5.5  13.9  13.5 
Infections and Infestations 
Influenza 7.5  11.7  6.3  4.1  4.2  4.1 
Nasopharyngitis 17.4  13.5  11.3  7.3  6.8  6.6 
Upper Respiratory Tract Infections  14.6  15.2  13.0  8.5  8.9  8.6 
Nervous System Disorder 
Dizziness 8.2  36.9  5.6  3.7  2.5  2.5 
Headache 22.8  24.5  11.5  7.5  13.1  12.7 
Psychiatric Disorders 
Abnormal Dreams  7.5  13.1  0.9  0.6  1.3  1.2 
Insomnia  12.1 11.0 6.1  4.0  5.1  4.9 
Respiratory, Thoracic and Mediastinal Disorders 
Cough 12.1  9.2  6.3  4.1  5.9  5.7 
Skin and Subcutaneous Tissue Disorders 
Rash 6.0  12.1  7.6  4.9  3.8  3.7 
Clinical AEs by System Organ Class (Incidence 2%
§) Drug-Related
¶ All Intensities 
Ear and Labyrinth Disorders 
Vertigo 1.8  3.2  0.9  0.6  0.0  0.0 
Gastrointestinal Disorders 
Abdominal Distension  1.1  1.4  2.2  1.4  1.7  1.6 
Abdominal Pain  1.4  2.5  1.5  1.0  1.3  1.2 
Diarrhea 5.0  9.6  3.2  2.1  5.1  4.9 
Dyspepsia 1.4  2.1  0.6  0.4  0.0  0.0 
Flatulence 3.6  5.0  1.9  1.3  1.3  1.2 
Nausea 8.5  9.9  4.1  2.7  4.6  4.5 
Vomiting 1.4  4.6  1.5  1.0  2.1  2.0 44    Current HIV Research, 2011, Vol. 9, No. 1  Teppler et al. 
Treatment Emergent Laboratory Abnormalities 
  As displayed in Table 3, treatment-emergent Grade 3 or 4 
abnormalities were uncommon in the STARTMRK 
treatment-naïve population, and were generally seen in the 
clinically more advanced BENCHMRK study population. 
The most common Grade 3 and 4 lab abnormalities 
(occurring in at least 4%) were absolute neutrophil count, 
fasting total and LDL-cholesterol, fasting triglycerides, 
alanine aminotransferase, aspartate aminotransferase, and 
CK, which were reported at similar frequencies between the 
groups within each study and are examined further in the 
section Detailed Review of Specific Safety Issues. 
  In the BENCHMRK studies, the frequency of patients 
with Grade 3 or 4 lipid values was slightly higher in the 
raltegravir group compared to the placebo group. However, 
the differences are small and are difficult to interpret, as 
many patients had pre-existing lipid disorders (44.8% in the 
raltegravir group and 43.9% in the placebo group), and lipid-
lowering agents were frequently used as prior and 
concomitant medications (data not shown). In order to 
address this confounding factor, a pre-specified analysis was 
conducted in STARTMRK and demonstrated minimal 
changes in lipid profile with raltegravir [2,3]. 
Detailed Review of Specific Safety Issues 
  Selected safety issues identified from clinical trials, post-
licensure reports, or as general concerns for antiretroviral 
agents were examined and are summarized below. 
Rash and Stevens-Johnson Syndrome (SJS) 
  In STARTMRK, rash occurred more frequently in the 
efavirenz group compared to the raltegravir group. In the 
BENCHMRK studies, the frequency of rash overall was 
higher in the raltegravir group compared to the placebo 
group, but drug-related rash occurred at comparable 
frequencies. Most cases of rash were mild to moderate. 
There were no serious AEs of rash and no cases of SJS in 
either population, and no patients discontinued raltegravir 
due to rash (Table 4). 
  In addition to the general review of rash, rash in the 
presence of darunavir was of interest because its common 
occurrence led to the premature termination of a phase I 
study in uninfected subjects in which raltegravir and 
(Table 2) contd….. 
STARTMRK BENCHMRK   
Raltegravir 
N=281 
Efavirenz 
N=282 
Raltegravir 
N=462 
PYR=708 
Placebo 
N=237 
PYR=244 
Proportion of Patients 
% %  %  Rate
† %  Rate
† 
General Disorders and Administrative Site Conditions 
Asthenia 2.1  2.5  1.5  1.0  0.4  0.4 
Fatigue 3.9  8.5  3.2  2.1  0.8  0.8 
Pyrexia 1.4  1.8  0.9  0.6  2.5  2.5 
Metabolism and Nutrition Disorders 
Anorexia 1.4  3.2  0.0  0.0  0.8  0.8 
Nervous System Disorders 
Dizziness 6.0  34.0  1.3  0.8  0.4  0.4 
Headache 9.3  13.8  4.8  3.1  5.1  4.9 
Somnolence 1.1  7.4  0.6  0.4  0.8  0.8 
Psychiatric Disorders 
Abnormal Dreams  7.1  13.1  0.4  0.3  0.8  0.8 
Insomnia 6.4  7.4  1.5  1.0  0.8  0.8 
Nightmare 2.5  5.0  0.0  0.0  0.0  0.0 
Skin and Subcutaneous Tissue Disorders 
Rash 1.1  8.2  1.1  0.7  1.7  1.6 
Rash Maculo-Papular  0.0  3.2  0.6  0.4  0.4  0.4 
PYR = Person Years at Risk. 
N = Number of patients in each treatment group. 
NA – Not applicable. No injectable antiretroviral medications administered in STARTMRK study. 
†Events per 100 person-years, with person-years at risk (PYR) calculated based on the overall endpoint. 
‡Determined by the investigator to be possibly, probably, or definitely drug-related. 
¶Determined by the investigator to be possibly, probably, or definitely drug-related to raltegravir/efavirenz (alone or in combination with OBT or tenofovir/emtricitabine. 
§Adverse Events presented in this table met the criteria for at least one parameter. 
%All cases due to enfuvirtide injections. 
Adverse Experience terms are from MedDRA Version 12.0. 
Note: For BENCHMRK Studies Raltegravir and Placebo were administered with Optimized Background Therapy (OBT). For STARTMRK Raltegravir and Efavirenz were 
administered with tenofovir/emtricitabine. 
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darunavir were co-administered
3, and due to the frequent use 
of darunavir in OBT in the phase III studies [5,6]. In the 
BENCHMRK studies, the frequency of rash in patients 
taking darunavir was slightly higher in the raltegravir group 
compared to the placebo group, while drug-related rash 
occurred at comparable frequencies. Exposure-adjusted rates 
of rash showed similar trends (Table 4). 
Depression and Suicidality 
  In STARTMRK, depression/suicidality occurred at 
similar frequencies for raltegravir and efavirenz. In the 
BENCHMRK studies, the frequency of 
depression/suicidality was lower than observed in the 
STARTMRK study and was similar in the raltegravir and 
placebo groups. SAEs of depression/suicidality were 
uncommon in both populations, and there were no 
discontinuations from the raltegravir group due to these 
events. Exposure-adjusted rates of depression/suicidality 
were similar overall and low for drug-related events (Table 
4). 
                                                 
3Anderson MS, Sekar V, Tomaka F, et al. Pharmacokinetic (PK) Evaluation 
of Darunavir/Ritonavir (DRV/r) and Raltegravir (RAL) in Healthy Subjects. 
Presented at 48th Interscience Conference on Antimicrobial Agents and 
Chemotherapy, Oct 2008 [Abstract A-962]. 
Immune Reconstitution Inflammatory Syndrome (IRIS) 
  In STARTMRK, IRIS occurred at similar frequencies in 
the raltegravir and efavirenz groups, and infrequently as an 
SAE; one raltegravir-treated patient discontinued due to 
IRIS. In the BENCHMRK studies, IRIS was reported at low 
and similar frequencies in the raltegravir and placebo groups; 
exposure-adjusted rates were similarly low (Table 4). 
Lipodystrophy 
  In STARTMRK, clinical AEs of lipodystrophy were 
uncommon. DEXA measurement showed minimal gains in 
body fat (Table 5), with no patterns of fat loss over 96 
weeks, suggesting that raltegravir is not associated with 
abnormal patterns of fat redistribution (lipodystrophy or 
lipoatrophy) over this period of observation. In the 
BENCHMRK studies, lipodystrophy occurred somewhat 
more often in the raltegravir group than the placebo group 
(Table  4), but this observation is confounded by high 
proportions of lipodystrophy-related diagnoses at baseline; 
44.8% in the raltegravir group and 43.9% in the placebo 
group, likely reflecting advanced HIV disease and 
substantial prior exposure to protease inhibitors. 
 
 
Table 3.  Grade 3 and 4 Laboratory Abnormalities, Phase III Studies
† 
 
STARTMRK BENCHMRK   
Raltegravir 
N=281 
Efavirenz 
N=282 
Raltegravir 
N = 462 
PYR = 708 
Placebo 
N = 237 
PYR = 244 
Laboratory Test  Grade 3 Threshold 
% % %  Rate
‡ %  Rate
‡ 
Hemoglobin   <7.4 (gm/dL)  0.7  0.7  1.1  0.7  0.8  0.8 
Absolute neutrophil count   <0.749 (10[3]/L) 2.5  1.1  4.1  2.7  3.8  3.7 
Platelet count   <49.999 (10[3]/L) 0.0  0.4  1.3  0.8  0.9  0.8 
Fasting LDL-C   190  (mg/dL) 1.1  6.5  5.8 2.8 6.5  4.5 
Fasting cholesterol   >300 (mg/dL)  0.0  4.1  9.9  6.2  6.2  5.7 
Fasting triglyceride   >751 (mg/dL)  0.4  1.5  9.9  6.2  6.7  6.1 
Fasting glucose   >251 (mg/dL)  1.1  0.0  2.7  1.7  0.9  0.8 
Total bilirubin   >2.6 x ULN (mg/dL)  0.7 0.0 3.7  2.4  2.5 2.5 
Creatinine   1.9 x ULN (mg/dL)  0.0 0.0 1.7  1.1  1.3 1.2 
Aspartate aminotransferase   >5.1 x ULN (IU/L)  2.8  2.5  4.8  3.1  4.2  4.1 
Alanine aminotransferase   >5.1 x ULN (IU/L)  1.8  2.5  5.2  3.4  3.8  3.7 
Alkaline phosphatase   >5.1 x ULN (IU/L)  0.0  0.7  1.1  0.7  1.7  1.6 
Pancreatic amylase   >2.1 x ULN (IU/L)  NA  NA  3.9  2.5  3.4  3.3 
Lipase   >3.1 x ULN (IU/L)  NA  NA  1.7  1.1  0.8  0.8 
Creatine kinase   10.0 x ULN (IU/L)  NA  NA  6.7  4.4  3.4  3.3 
PYR = Person Years at Risk. 
N = Number of patients in each treatment group. 
ULN = Upper Limit of Normal. 
NA = Not Applicable. These tests not performed for STARTMRK study. 
†For inclusion in this analysis, both a baseline and at least one on-treatment laboratory value had to be present. Only patients with a worsened grade from baseline were included. A 
patient was listed with a Grade X event if his/her highest grade during the treatment was X. 
‡Events per 100 person-years, with person-years at risk (PYR) calculated based on the overall endpoint. 
Note: For BENCHMRK Studies Raltegravir and Placebo were administered with Optimized Background Therapy (OBT). For STARTMRK Raltegravir and Efavirenz were 
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Increase in Creatine Phosphokinase (CK) with Clinical 
Manifestations, Myopathy, and Rhabdomyolysis 
  In the STARTMRK study, there was one (0.4%) serious 
clinical AEs of myopathy in the raltegravir group, which the 
investigator considered not drug-related. There were no 
reports of myositis or rhabdomyolysis; CK was not routinely 
monitored. In the BENCHMRK studies, CK was routinely 
monitored and treatment-emergent Grade 3 or 4 CK values 
Table 4.  Summary of Specific Safety Issues, Phase III Studies  
 
STARTMRK BENCHMRK   
Raltegravir 
N=281 
Efavirenz 
N=282 
Raltegravir 
N=462; PYR=708 
Placebo 
N=237; PYR=244 
 
% % %  Rate
† %  Rate
† 
Rash in Overall Population 
All   9.6  20.9  11.3  7.3  6.3  6.1 
Drug-related
‡   1.8  13.8  2.6  1.7  3.8  3.7 
Serious   0.0  0.0  0.0  0.0  0.0  0.0 
Discontinued   0.0  1.1  0.0  0.0  0.0  0.0 
Rash in Patients Who Received OBT with Darunavir 
All    NA NA 17.4 10.9  4.8  3.8 
Drug-related
‡ NA  NA  3.9  2.4  2.9  2.3 
Serious   NA  NA  0.0  0.0  0.0  0.0 
Discontinued   NA  NA  0.0  0.0  0.0  0.0 
Rash in Patients Who Received OBT without Darunavir 
All   NA  NA  6.3  4.2  7.5  8.8 
Drug-related
‡   NA  NA  1.6  1.1  4.5  5.3 
Serious   NA  NA  0.0  0.0  0.0  0.0 
Discontinued   NA  NA  0.0  0.0  0.0  0.0 
Depression/Suicidality 
All   7.5  8.9  3.7  2.4  5.5  5.3 
Drug-related
‡   2.5  3.9  0.6  0.4  0.8  0.8 
Serious 0.7  0.7  0.4  0.3  0.8  0.8 
Discontinued 0.0  0.4  0.0  0.0  0.0  0.0 
IRIS 
All   6.8  4.6  0.4  0.3  0.4  0.4 
Drug-related
‡ 3.2  1.1  0.0  0.0  0.4  0.4 
Serious   1.8  0.7  0.4  0.3  0.0  0.0 
Discontinued   0.4  0.0  0.0  0.0  0.0  0.0 
Lipodystrophy 
All   0.0  0.7  5.6  3.7  3.0  2.9 
Drug-related
‡   0.0  0.4  4.8  3.1  3.0  2.9 
Serious   0.0  0.0  0.0  0.0  0.0  0.0 
Discontinued   0.0  0.0  0.0  0.0  0.0  0.0 
Increased CK with Clinical Manifestations (Myopathy, Myositis, or Rhabdomyolysis) 
Grade 3 or 4 CK  NA  NA  6.7  4.4  3.4  3.3 
Discontinued Due to Laboratory AE  0.0  0.0  0.0  0.0  0.0  0.0 
Myopathy, Myositis or Rhabdomyolysis 0.4  0.0  0.2  0.1  0.4  0.4 
 
PYR = Person Years at Risk. 
N = Number of patients in each treatment group. 
†Events per 100 person-years, with person-years at risk (PYR) calculated based on the overall endpoint. 
‡Determined by the investigator to be possibly, probably, or definitely drug related. 
NA = Not Applicable. 
Note: For BENCHMRK Studies Raltegravir and Placebo were administered with Optimized Background Therapy (OBT). For STARTMRK Raltegravir and Efavirenz were 
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occurred more frequently for raltegravir than placebo. 
Exposure-adjusted rates were also somewhat higher for 
raltegravir. There was a single (0.2%) report of myositis with 
an associated Grade 2 CK value in the raltegravir group, 
which the investigator judged as related to ritonavir (in 
OBT), and one (0.1%) report of myopathy in the placebo 
group which was considered not drug-related by the 
investigator. There were no reports of rhabdomyolysis in 
either group. There were no raltegravir discontinuations 
related either to the CK elevations or the clinical AEs (Table 
4). 
Hepatic Safety: Increase in Liver Enzymes (and Related 
Clinical Hepatic Events) 
  In the STARTMRK study, treatment-emergent Grade 3 
or 4 elevations of alanine aminotransferase (ALT) and 
aspartate aminotransferase (AST) respectively, occurred in 
1.8% and 2.8% of  patients in the raltegravir group compared 
to 2.5% for both parameters in the efavirenz group. 
ALT/AST elevations did not limit raltegravir therapy; there 
were 3 discontinuations in the efavirenz group. Grade 3 and 
4 bilirubin elevations were uncommon (Table 6). 
  In the BENCHMRK studies, treatment emergent Grade 3 
or 4 elevations of ALT and AST respectively, occurred in 
5.2% and 4.8% of patients in the raltegravir group compared 
to 3.8% and 4.2% in the placebo group. One patient in the 
raltegravir group discontinued therapy due to ALT/AST 
elevation (considered not drug-related). The exposure-
adjusted rates per 100 PYR for Grade 3 or 4 ALT and AST 
were, respectively, 3.4 and 3.1 in the raltegravir group 
compared to 3.7 and 4.1 in the placebo group. Grade 3 or 4 
bilirubin elevations were uncommon (Table 6) and mostly 
associated with atazanavir use. 
  In all 3 studies, clinical hepatic AEs were uncommon and 
occurred at similar frequencies in the raltegravir and 
comparator groups. In the BENCHMRK studies, serious 
hepatic events were infrequent and none resulted in death; 
one patient in the raltegravir group discontinued due to an 
AE of hepatitis (Table 6). 
  Review of the safety profile of raltegravir was also 
performed in the subgroup of patients co-infected with 
hepatitis B and/or C, which was present in approximately 6% 
of STARTMRK and 16% of BENCHMRK-1 patients. 
 
In general, Grade 3 or 4 aminotransferase elevations were 
more common in co-infected patients in all treatment groups, 
compared to patients without co-infection, but were not 
associated with Grade 3 or 4 bilirubin elevations. Clinical 
hepatic events were very uncommon, were not serious and 
did not limit therapy. 
Malignancies 
  The present analysis of malignancies was performed 
consistently with previous analyses [4] and employed two 
case definitions. For the double-blind comparison, exposure-
adjusted rates per 100 PYR of cancer for the 3 studies were 
0.96 for raltegravir and 1.28 for comparator (efavirenz or 
placebo), resulting in a RR (95% CI) of 0.75 (0.30, 1.91) 
using the National Cancer Institute/American Cancer Society 
(NCI/ACS) definition. Using a broader definition that 
includes recurrences, carcinomas in situ, and non-melanoma 
skin cancers (such as basal cell and squamous cell 
carcinomas), the rates per 100 PYR were 2.02 and 2.33, 
respectively, resulting in a RR of 0.87 (0.46, 1.67). Similar 
results were obtained when the open-label phases of the 
studies were included (data not shown). Using time-to-event 
analysis, the occurrence of cancer events for raltegravir using 
either case definition diminished after the first 3 months of 
study and remained relatively flat compared to the 
comparator group (Fig. 1). The 96-week data indicate the 
risk of cancer is similar for raltegravir and comparator 
groups whether all cancers or only NCI/ACS events are 
included, and there is no specific cancer risk associated with 
raltegravir treatment. 
Meta-Analysis 
  The cumulative meta-analysis included 1771 PYR of 
raltegravir 400mg BID exposure (over 2.5 fold greater 
compared with the STARTMRK and BENCHMRK studies 
alone). Overall trends for both number (%) and exposure-
adjusted rates (1771 PYR for raltegravir vs 981 PYR for 
comparator) for all-causality, drug-related, serious, and 
serious drug-related adverse experiences (Table 7), as well as 
treatment-emergent laboratory abnormalities (Table 8), were 
broadly similar to those observed in the phase III studies. No 
new safety concerns for raltegravir were identified. Further 
details of the meta-analysis can be found in 
Supportive/Supplementary Material. 
 
Table 5.  Percent Change from Baseline in Whole Body Composition by DEXA in STARTMRK 
 
 Raltegravir  Efavirenz   
Baseline  Mean %  Baseline  Mean % 
Week N 
Mean (gm)  Change†(95% CI) 
N 
Mean (gm)  Change†(95% CI) 
0   55   20408.54      56   17542.25    
48   40   20095.34   18.10 (6.22, 29.98)    46   17776.56   19.99 (12.42, 27.57)  
96   37   21487.02   19.63 (3.26, 36.01)    38   17566.83   21.04 (12.16, 29.92)  
N = Number of patients in the treatment group. 
†Mean % change from baseline and are based on the measurements of the patients who were measured at baseline and the time point assessed. 
The DEXA re-scan (for the baseline visit) values were taken as the baselines for 7 patients and clinically deemed acceptable, when the original baseline scan readings were not 
available. 
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DISCUSSION 
  Raltegravir has demonstrated a favorable safety profile in 
addition to its potent efficacy based on data from 
comparative phase III trials against efavirenz (with 
background of tenofovir and emtricitabine) in treatment-
naïve patients [2,3] and against placebo (with OBT) in 
treatment-experienced patients [4-6]. Long-term data from 
the phase II studies in treatment-naïve and treatment-
experienced populations, which include data to week 144, 
show a similar safety profile [9,10] 
2,4. 
                                                 
4Gatell J, Nguyen B-Y, Grinsztejn B, et al. 144-Week Efficacy and Safety 
of Raltegravir (RAL) in Treatment-Experienced Patients [abstract]. 
Presented at the 47th Annual Meeting of the Infectious Diseases Society of 
America, Philadelphia PA, October 2009. 
Table 6.  Liver Function Tests and Hepatobiliary Clinical Events, Phase III Studies 
 
STARTMRK BENCHMRK   
Raltegravir 
N=281 
Efavirenz 
N=282 
Raltegravir 
N=462 
PYR=708 
Placebo 
N=237 
PYR=244 
Adverse Experience (AE) 
% %  %  Rate
† %  Rate
† 
Overall Population: Liver Function Tests 
Grade 3 or 4 ALT  1.8  2.5  5.2  3.4  3.8  3.7 
Grade 3 or 4 AST  2.8  2.5  4.8  3.1  4.2  4.1 
Grade 3 or 4 Total Bilirubin  0.7  0.0  3.7  2.4  2.5  2.5 
Discontinued Due to Laboratory AE of ALT/AST/Bilirubin  0.0  0.7  0.2  0.1  0.0  0.0 
Overall Population: Hepatobiliary Clinical Events
‡ 
All AEs  0.7  0.4  1.1  N/D  1.3  N/D 
Drug-related
§ AEs  0.4  0.4  0.9  N/D  1.3  N/D 
Serious AEs  0.0  0.0  0.2  N/D  0.4  N/D 
Discontinued Due to Clinical AEs  0.0  0.0  0.2  N/D  0.0  N/D 
Patients With Hepatitis B and/or C Co-Infection
%: Liver Function Tests  
Grade 3 or 4 ALT  5.6  12.5  13.0  8.0  8.1  9.1 
Grade 3 or 4 AST  11.1  6.3  10.4  6.4  2.7  3.0 
Grade 3 or 4 Total Bilirubin  0.0  0.0  3.9  2.4  5.4  6.0 
Patients With Hepatitis B and/or C Co-Infection
%: Hepatobiliary Clinical Events 
All  AEs  0.0 0.0 1.3  N/D 0.0 N/D 
Drug-related
§  AEs  0.0 0.0 1.3  N/D 0.0 N/D   
Serious  AEs  0.0 0.0 0.0  N/D 0.0 N/D 
Discontinued Due to Clinical AEs  0.0  0.0  0.0  N/D  0.0  N/D 
Patients Without Hepatitis B and/or C Co-Infection
%: Liver Function Tests  
Grade 3 or 4 ALT  1.5  1.9  3.6  2.4  3.0  2.9 
Grade 3 or 4 AST  2.3  2.3  3.6  2.4  4.5  4.3 
Grade 3 or 4 Total Bilirubin  0.8  0.0  3.6  2.4  2.0  1.9 
Patients Without Hepatitis B and/or C Co-infection
%: Hepatobiliary Clinical Events 
All AEs  0.8  0.4  1.0  N/D  1.5  N/D 
Drug-related
§ AE  0.4  0.4  0.8  N/D  1.5  N/D 
Serious AE  0.0  0.0  0.3  N/D  0.5  N/D 
Discontinued Due to Clinical AE  0.0  0.0  0.3  N/D  0.0  N/D 
PYR = Person Years at Risk. 
N = Number of patients in each treatment group. 
†Events per 100 patient-years. 
‡Hepatobiliary Clinical Events include: acute hepatitic failure, hepatic cirrhosis, hepatic steatosis, hepatitis, hepatitis acute, hepatitis toxic, and jaundice. 
§Determined by the investigator to be possibly, probably, or definitely drug-related. 
%Number of patients with Hepatitis B and/or C Infection: STARTMRK: Raltegravir = 18, Efavirenz = 16 and BENCHMRK: Raltegravir = 77, Placebo = 37. Number of patients 
without Hepatitis B and/or C Infection: STARTMRK: Raltegravir = 263, Efavirenz = 266 and BENCHMRK: Raltegravir = 385, Placebo = 200. 
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  Rash is frequently observed with several antiretroviral 
and other agents commonly used in the treatment of HIV 
infection [11-14]. In clinical trials, rash was observed in 
raltegravir-treated patients at a higher frequency than 
placebo but at a lower frequency than efavirenz. The 
incidence of rash was also higher among patients taking 
raltegravir and darunavir than in patients taking raltegravir 
without darunavir or darunavir without raltegravir. In 
general, rash was reported as mild to moderate and did not 
lead to discontinuation of raltegravir. It is important to note 
that raltegravir is only administered in combination with 
other antiretroviral agents, thus the reports of rash are 
confounded by concomitant antiretroviral and often other 
therapies, many known to be associated with rash. A number 
of antiretroviral agents have been associated with SJS [15]. 
This event was added to the raltegravir labeling after several 
post-marketing reports of SJS were received, even though 
the reports were confounded by the use of concomitant 
medications. There were no cases of SJS in the raltegravir 
phase III studies. 
  Depressive disorders appear to be more common in 
persons with HIV infection than in the general population 
[16]. Neuropsychiatric symptoms have been associated with 
efavirenz, particularly in the short term after initiation of 
therapy [17-22]. Depression, including suicidal thoughts and 
behaviors, was added to the raltegravir product labeling after 
identification of several post-marketing cases, including 
those reported in the literature [23]. In the phase III studies 
of raltegravir, depression occurred at generally similar rates 
between raltegravir and comparator, and one suicide attempt 
was reported. 
  IRIS has been reported with multiple HAART regimens 
[24-30] and is often associated with a specific diagnosis of 
an opportunistic infection or malignancy. Reports of IRIS in 
patients receiving raltegravir are consistent with what has 
been reported with other classes of antiretroviral agents. 
  Lipodystrophy is a common metabolic complication of 
antiretroviral therapy [31-38]. The incidence of 
lipodystrophy in the raltegravir phase III trials was low in 
treatment-naïve patients overall. Analysis of body fat content 
by dual energy x-ray absorptiometry (DEXA) scanning in a 
subset of patients showed similar degrees of fat gain through 
96 weeks for each treatment group, with a greater increase in 
trunk than limb adiposity [3]. Also, raltegravir had minimal 
effect on serum lipid levels in treatment-naïve patients [2,3]. 
In treatment-experienced patients, lipodystrophy occurred at 
generally similar rates in the raltegravir and placebo groups, 
but these rates are confounded by the background prevalence 
of lipodystrophy (approximately 44-45% in both groups) and 
frequent concomitant use of other classes of antiretroviral 
therapies for which lipodystrophy/fat maldistribution have 
been reported. 
  Elevations of CK have been seen in clinical trials at a 
higher incidence for raltegravir than placebo; however, these 
were generally isolated laboratory findings, without clinical 
manifestations and did not lead to discontinuation. Although 
not seen in the comparative phase III studies, there have been 
several reports of rhabdomyolysis in expanded access 
programs for raltegravir, as well as in the post-marketing 
environment, including some reports in patients with 
confounding factors, such as concomitant use of medications 
known to be associated with this condition, including HMG-
CoA reductase inhibitors and fibric acid derivatives. 
Rhabdomyolysis is included in product labeling for 
raltegravir. 
  Increased liver enzymes and, to a lesser degree, related 
clinical hepatic events, are common complications of 
antiretroviral and other therapies in HIV infected individuals; 
furthermore, interpretation may be confounded by the common 
occurrence of dual infection with HIV and hepatitis B or C 
virus. In clinical trials, aminotransferase elevations occurred at 
modest and similar rates in raltegravir and comparator groups. 
While these abnormalities were more frequent in patients with 
(than without) viral hepatitis co-infection, they occurred 
similarly in the raltegravir and comparator groups. 
Aminotransferase abnormalities were not associated with 
unexplained hyperbilirubinemia or clinical hepatic toxicity, and 
rarely limited therapy. Thus, raltegravir does not appear to be 
associated with important hepatotoxic effects, including in 
patients with hepatitis B or C co-infection. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Kaplan-Meier estimates of time to malignancy event in the Phase III studies (Protocols 018, 019, and 021) using a broad cancer 
definition (Panel A) and the NCI/ACS definition (Panel B). The NCI/ACS definition does not include recurrence, carcinoma in situ, or non-
melanoma skin events. *All patients also received OBT (in the BENCHMRK studies) or tenofovir with emtricitabine (in the STARTMRK 
study). 50    Current HIV Research, 2011, Vol. 9, No. 1  Teppler et al. 
   
Table 7.  Summary of Clinical Adverse Experiences, Meta-Analysis Population 
 
Raltegravir 400 mg b.i.d. 
N=1298 
PYR=1771 
Comparators 
N=954 
PYR=981  Proportion of Patients 
% Rate
† %  Rate
† 
Clinical Adverse Experience (AE) Summary 
With one of more AEs  84.8  62.2  78.6  76.5 
With drug-related
‡ AEs  42.2  30.9  48.6  47.3 
With serious AEs  14.3  10.5  10.8  10.5 
With serious drug-related
‡ AEs  1.5  1.1  1.8  1.7 
Who died  1.2  0.9  0.8  0.8 
Discontinued due to AEs  2.6  1.9  3.6  3.5 
Discontinued due to drug-related
‡ AEs  0.9  0.7  2.2  2.1 
Clinical AEs by System Organ Class (Incidence 10%
§) All Causality, All Intensities 
Gastrointestinal Disorders 
Diarrhea 15.7  11.5  19.3  18.8 
Nausea 11.5  8.4  10.6  10.3 
Infections and Infestations 
Nasopharyngitis 10.8  7.9  7.4  7.2 
Upper Respiratory Tract Infection  12.1  8.9  9.4  9.2 
Nervous System Disorders 
Dizziness 6.0  4.4  13.3  12.9 
Headache 13.2  9.7  14.0  13.7 
Clinical AEs by System Organ Class (Incidence 2%
§) Drug-Related
% All Intensities 
Gastrointestinal Disorders 
Diarrhea 3.2  2.3  6.9  6.7 
Flatulence 2.3  1.7  2.6  2.5 
Nausea 5.2  3.8  5.7  5.5 
Vomiting 1.4  1.0  2.5  2.4 
General Disorders and Administration Site Conditions 
Fatigue 2.9  2.1  3.2  3.2 
Nervous System Disorders 
Dizziness 3.0  2.2  11.6  11.3 
Headache 5.6  4.1  6.9  6.7 
Somnolence 0.8  0.6  2.6  2.5 
Psychiatric Disorders 
Abnormal Dreams  2.5  1.8  4.8  4.7 
Insomnia 3.4  2.5  3.1  3.1 
Skin and Subcutaneous Tissue Disorders 
Rash 0.8  0.6  2.9  2.9 
PYR = Person Years at Risk. 
N= Number of patients in each treatment group. 
†Events per 100 patient-years. 
‡Determine by the investigator to be possibly, probably, or definitely drug-related. 
§Adverse Events presented in this table met the criteria for at lease one parameter. 
%For Protocols 004, 005, 018, 019, and 021 determined by the investigator to be drug-related to raltegravir, efavirenz, or placebo (alone or in combination with ART). For Protocols 
032 and 033 determined by the investigator to be drug-related or not related. 
Adverse Experience terms are from MedDRA version 12.0 for Protocols 004, 005, 018, 019, and 021 and from MedDRA 11.1 for Protocols 032 and 033. 
Note: Comparators include efavirenz in Protocols 004 and 021, placebo in Protocols 005, 018, and 019, lopinavir/ritonavir in Protocols 032 and 033. Long-Term Safety of Raltegravir  Current HIV Research, 2011, Vol. 9, No. 1    51 
  Malignancies have been closely monitored since early in 
the development program after a possible signal was 
identified with slight excess in cancers observed in the 
BENCHMRK studies at the first interim analysis of partial 
data. With additional follow-up in subsequent analyses, the 
data demonstrate a RR (95% CI) of 0.75 (0.30, 1.91) 
indicating no difference in cancer risk between raltegravir 
and comparator. Possible explanations for the early, transient 
signal include a premature assessment of limited data, and 
the occurrence of IRIS acting to bring subclinical 
malignancies to early clinical detection in the setting of 
prompt virologic suppression and CD4 cell recovery. Two 
observational cohort studies have begun which will further 
assess this issue in the post-licensure environment. 
  This paper has presented all available comparative phase 
III data for raltegravir. The data have some limitations: in the 
BENCHMRK studies in highly treatment-experienced 
patients, the patient year exposure was 2-3 fold higher for 
raltegravir than comparator due to frequent virologic failure 
in the placebo group, resulting in retention of patients with 
the most advanced disease in the raltegravir group. Provision 
of both unadjusted frequencies and exposure adjusted rates 
for BENCHMRK data were an effort to offer an unbiased 
perspective on the occurrence of early versus late adverse 
experiences. Women represented <20% of patients enrolled 
in these phase III studies. Other limitations include the 
defined inclusion/exclusion criteria used in the context of 
clinical trials. However, these studies allowed enrollment of 
patients with advanced HIV disease, substantial laboratory 
abnormalities, active hepatitis B or C co-infection, and stable 
prior cancer at study entry, in order to include a reasonably 
representative study population. In addition, the 
BENCHMRK studies allowed patients to use investigational 
agents in their OBT. 
  A cumulative meta-analysis of safety was conducted 
including all available data from adult patients in the 
raltegravir clinical development program who received the 
400 mg bid dose, thus including substantial additional 
raltegravir exposure beyond the phase III studies included in 
this report. This meta-analysis demonstrated a safety profile 
generally consistent with the STARTMRK and 
BENCHMRK studies, acknowledging the diversity of a 
population including both treatment-naïve and highly 
treatment-experienced patients. 
  In aggregate, data from the raltegravir clinical 
development program have demonstrated potent and durable 
efficacy in a broad patient population with HIV infection [2-
6]. This manuscript provides an overview of the favorable 
safety profile established for raltegravir to date, and supports 
the use of this agent in combination regimens for the 
treatment of HIV infection. The safety of raltegravir will 
continue to be monitored in ongoing clinical trials, including 
studies in other patient populations such as pediatric patients, 
and by pharmacovigilance activities in the marketed 
Table 8.  Grade 3 and 4 Laboratory Abnormalities, Meta-Analysis Population
† 
 
Raltegravir 400 mg b.i.d. 
N=1298 
PYR = 1771 
Comparators 
N=954 
PYR = 981  Laboratory Test  Grade 3 Threshold 
% Rate
‡ %  Rate
‡ 
Hemoglobin <7.4  (gm/dl)  0.5  0.4  0.4  0.4 
Absolute neutrophil count  <0.749 (10[3]/microL)  2.2  1.6  1.5  1.4 
Platelet count  <49.999 (10[3]/microL)  0.6  0.5  0.3  0.3 
Fasting LDL-C  190 (mg/dL)  2.6  1.6  4.5  3.7 
Fasting Cholesterol  >300 (mg/dL)  4.0  2.8  4.1  3.7 
Fasting Triglyceride  >751 (mg/dL)  4.0  2.8  3.5  3.2 
Fasting Glucose  >251 (mg/dL)  1.3  0.9  0.2  0.2 
Total bilirubin  >2.6 (mg/dL)  1.9  1.4  1.2  1.1 
Creatinine  1.9 x ULN (mg/dL)  0.7  0.5  0.4  0.4 
Aspartate aminotransferase  >5.1 x ULN (IU/L)  3.1  2.3  2.1  2.0 
Alanine aminotransferase  >5.1 x ULN (IU/L)  3.1  2.3  2.2  2.1 
Alkaline phosphatase  >5.1 x ULN (IU/L)  0.5  0.3  0.6  0.6 
Pancreatic amylase
§  >2.1 x ULN (IU/L)  3.5  2.0  2.5  2.2 
Lipase
§  >3.1 x ULN (IU/L)  1.1  0.9  0.3  0.4 
Creatine kinase
§  10.0 x ULN (IU/L)  7.2  4.2  3.4  3.0 
PYR = Person Years at Risk. 
N = Number of patients in each treatment group. 
ULN = Upper Limit of Normal. 
†For inclusion in this analysis, both a baseline and at least one on-treatment laboratory value had to be present. Only patients with a worsened grade from baseline were included. A 
patient was listed with a Grade X event if his/her highest grade during treatment was X. 
‡Events per 100 person-years, with person-years at risk (PYR) calculated based on the overall endpoint. 
§Protocol 021 did not routinely collect pancreatic amylase, lipase, or creatine kinase. Protocols 032 and 033 did not routinely collect pancreatic amylase or lipase. 
Note: Comparators include efavirenz in Protocols 004 and 021, placebo in Protocols 005, 018, and 019, lopinavir/ritonavir in Protocols 032 and 033. 52    Current HIV Research, 2011, Vol. 9, No. 1  Teppler et al. 
environment, which include the continuous review of 
spontaneous reports of adverse experiences, and the conduct 
of prospective observational cohort studies. 
SUPPORTIVE/SUPPLEMENTARY MATERIAL 
1.  Cumulative meta-analysis: description of methods 
and results. 
2.  Table: Patient demographics, meta-analysis 
population 
3.  Table: Summary of specific safety issues, meta-
analysis population 
4.  Table: Liver function tests and hepatobiliary clinical 
events, meta-analysis population 
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ABBREVIATIONS 
ADC =  AIDS-defining  conditions 
AE =  Adverse  event 
ALT =  Alanine  aminotransferase 
AST =  Aspartate  aminotransferase 
CI =  Confidence  interval 
CK =  Creatine  phosphokinase 
DAIDS  =  Division of AIDS 
DB =  Double-blind 
DEXA  =  Dual energy x-ray absorptiometry 
HAART  =  Highly active antiretroviral therapy 
HIV =  Human  immunodeficiency  virus 
IRIS  =  Immune reconstitution inflammatory   
     syndrome 
MedDRA = Medical Dictionary for Drug Regulatory 
Affairs 
NCI/ACS  =  National Cancer Institute/American Cancer   
     Society 
OBT  =  Optimized background therapy 
PYR =  Person-years 
RR =  Relative  risk 
SAE  =  Serious adverse event 
SJS =  Stevens-Johnson  syndrome 
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